Watson and HRA Pharma Announce Exclusive Licensing Agreement to Commercialize Novel Emergency Contraceptive in the U.S.
New data published in The Lancet demonstrate effective pregnancy prevention as compared to currently available emergency contraceptive options.

  Read more…

Breaking News in Emergency Contraception: HRA Pharma Unveils Clinical Data on ellaOne^®.
Groundbreaking clinical trials on new generation emergency contraceptive published simultaneously in The Lancet and Obstetrics & Gynecology.

  Read more…

HRA Pharma Expands to Spain and Launches ellaOne^®.
Independent niche pharmaceutical company tackles its fifth European market;local commercial operations to support its new generation emergency contraceptive

  Read more…

HRA Pharma’s NorLevo^® on its way to becoming the first emergency contraceptive pill available in Japan.
HRA Pharma’s partner Sosei signed distribution agreement with ASKA for commercialisation of NorLevo^® in Japan.

  Read more…

HRA Pharma’s emergency contraceptive ella^® in motion in Asia
HRA Pharma and Orient Europharma enter into a distribution agreement to commercialize ella^®, a new generation emergency contraceptive, in Taiwan, Hong Kong and Macao.

  Read more…

HRA Pharma Marks First Step for ella^® in Asia.
HRA Pharma and Hyphens enter into a license and supply agreement to commercialize ella^®, a new generation emergency contraceptive, in Singapore and Malaysia.

  Read more…

HRA Pharma Launches ellaOne^® in Europe.
New generation emergency contraception now commercially available in France, Germany and the United Kingdom, in anticipation of upcoming launch throughout European Union.

  Read more…

HRA Pharma Announces European Marketing and Distribution Agreement with Acrux.
European specialist in reproductive health and endocrinology adds novel transdermal estradiol spray to growing product portfolio.

  Read more…

HRA Pharma Named Finalist for the 2009 Scrip Awards and the 2009 Clinical Research Excellence Awards.

  Read more…

HRA Pharma Reinforces Operational Presence in Europe with Italian Subsidiary.
Independent company with international mindset and niche therapeutic solutions now has offices in four European countries.

  Read more…

NorLevo®, HRA Pharma's Emergency Contraceptive Pill, Now Available in Canada.
European specialist in reproductive health and endocrinology teams with Bayer Inc. for launch of pioneering product.

  Read more…

HRA Pharma Marks Next Step in European Expansion with UK Subsidiary.

  Read more…

HRA Pharma Granted European Marketing Authorization for ellaOne®.
Next generation emergency contraceptive will first be launched in UK, Germany and France as company expands international operations.

  Read more…

HRA PHARMA AND PREGLEM ANNOUNCE SUCCESSFUL COMPLETION OF PHASE IIB FOR ULIPRISTAL ACETATE FOR THE TREATMENT OF UTERINE FIBROIDS.

  Read more…

HRA Pharma Appoints Erin Gainer as CEO to Lead Company Through Next Phases of International Growth.
Founder André Ulmann becomes Chairman.

  Read more…

HRA Pharma and Nycomed Reinforce Partnership with Marketing and Distribution Agreement for ellaOne®
Combination of strengths will benefit women in Nordic and Baltic countries; HRA Pharma gearing up for EU marketing authorization of revolutionary product in reproductive health.

  Read more…

HRA Pharma Receives CHMP Positive Opinion for ellaOne®
Leader in reproductive health now one step closer to providing greater contraceptive solutions to women in the European Union.

  Read more…

HRA Pharma and Gedeon Richter Enter into Marketing and Distribution Agreement
Specialists in emergency contraception team together for women's health in CEE and CIS countries

  Read more…

HRA Pharma Strengthens European Operations with German Affiliate.
Specialist in reproductive health and endocrinology marks first step in reinforcing operational presence on the continent; new entity to spearhead growth in one of Europe's largest healthcare markets

  Read more…

HRA Pharma enters licensing agreement with PregLem to develop and commercialise ulipristal for gynecological disorders.
HRA Pharma announced today that it has entered into a licensing agreement with PregLem, a Swiss specialty biopharmaceutical company, for the European development and commercialisation of HRA Pharma's selective progesterone receptor modulator, ulipristal, for the treatment of various benign gynecological disorders

  Read more…

Being aware that humanitarian programs should not be restricted to the company's area of business, and because cultural development is a necessity for development, HRA has sponsored an award at the "Rencontres africaines de la photographie" aimed to reward the work of a young African photographer who displays unique talent and a potential for excellence.

  Read more…

HRA Pharma is sponsoring the "Afrique en créations" prize aimed to reward the work of a young, talented African photographer.

  Read more

HRA Pharma commences UK-based Phase III trial of Ella^®, a second-generation emergency contraceptive
HRA Pharma today announced recruitment has begun into a UK-based pivotal Phase III study to evaluate the Company's second-generation emergency contraceptive, Ella^®. The study will be conducted across nine NHS family planning clinics in the UK.

  Read more…

HRA Pharma invest an additional € 2.5 M in cell therapy through its subsidiary Celogos
HRA Pharma, a private pharmaceutical company focused on innovative treatments in women's health and endocrinology, announced today that it has invested a further €2.5 M in its subsidiary Celogos. The funds will allow the French biotech company, a pioneer in the development of cell-based therapies for muscle disorders, to ramp up the on-going clinical development of its pipeline.

  Read more…

Stem Cell Sciences and Celogos sign a licensing deal on autogenous myoblast transplantation
Celogos, the biotechnology company focused on the development and production of innovative cell-based technologies in the field of cellular medicine, and Stem Cell Sciences KK (SCSKK), the bio-venture company specialized in regenerative medicines, have reached an agreement on the licensing of technologies for myoblast cell implantation for the treatment of stress urinary incontinence.

  Read more…

HRA Pharma commences US Phase III trial of second-generation emergency contraceptive
HRA Pharma today announced the start of a pivotal multi-centre Phase III study evaluating its proprietary second-generation emergency contraceptive – Ella^®. The study will be conducted in sixteen clinics affiliated with Planned Parenthood Federation of America (PPFA) in seven different US states.

  Read more…